Treatment for Bladder Polyp
The first-line treatment for a bladder polyp is transurethral resection of the bladder tumor (TURBT), followed by risk-stratified intravesical therapy based on pathology results.
Initial Surgical Management
The cornerstone of treatment is complete endoscopic resection via TURBT 1. This serves both diagnostic and therapeutic purposes, allowing for:
- Complete histopathologic evaluation including grade and stage
- Assessment of muscle invasion in the specimen
- Determination of risk stratification for subsequent therapy
A critical pitfall: If no muscle (muscularis propria) is present in the initial TURBT specimen for high-grade tumors, a repeat TURBT should be strongly considered or performed 4-6 weeks later 1. This is essential because 20-40% of patients will have residual tumor or unrecognized muscle-invasive disease when muscle is absent from the initial specimen 2.
Risk-Stratified Post-TURBT Management
Low-Risk Disease (Ta, Low-Grade)
- Single immediate intravesical chemotherapy instillation (e.g., mitomycin C) within 24 hours of TURBT 1
- This reduces 5-year recurrence from 45% to 59% versus TURBT alone
- Followed by cystoscopic surveillance at 3 months, then increasing intervals
- Avoid immediate instillation if extensive TURBT or bladder perforation suspected 2
Intermediate-Risk Disease
12 months of BCG instillation therapy is recommended 1:
- Induction: 6 weekly BCG instillations
- Maintenance: 3 BCG instillations each at 3,6, and 12 months after induction start
- Alternative: Intravesical chemotherapy for maximum 1 year
- BCG shows 32% reduction in recurrence risk versus mitomycin C (P < 0.0001) 1
High-Risk Disease (T1, High-Grade, or CIS)
Full-dose intravesical BCG for 1-3 years (minimum 1 year) is the standard 1:
- Induction: 6 weekly instillations
- Maintenance: 3 weekly instillations at 3,6,12,18,24,30, and 36 months
- Three-year maintenance significantly reduces recurrence versus 1-year (HR 1.61,95% CI 1.13-2.30, P = 0.01) 1
- This benefit applies only to high-risk tumors, not intermediate-risk
For T1 tumors specifically, repeat TURBT is strongly advised when 2:
- Initial resection was incomplete
- No muscle in specimen
- Lymphovascular invasion present
- Residual disease found after second resection warrants consideration of cystectomy
BCG-Unresponsive Disease
Radical cystectomy should be offered for BCG-unresponsive high-grade tumors (T1/HG, Ta/HG, CIS) due to high progression risk 1. BCG-unresponsive is defined as:
- BCG-refractory: persistent high-grade disease at 6 months despite adequate BCG
- BCG-relapsing: recurrence of high-grade disease within 6 months after achieving disease-free state
Alternative for surgical non-candidates: Thermo-chemotherapy can achieve 2-year disease-free survival in 47% 1
Muscle-Invasive Disease
If pathology reveals muscle invasion (≥T2):
- Radical cystectomy with pelvic lymphadenectomy 1
- Strongly consider neoadjuvant cisplatin-based combination chemotherapy (3-4 cycles) 1
- Alternative for selected patients: Multimodal bladder-sparing treatment (maximal TURBT + concurrent chemotherapy + radiotherapy) 3
Benign Polyps
For truly benign fibroepithelial polyps (rare, typically in children/young adults):
- Transurethral resection is curative 4, 5, 6
- Excellent prognosis with minimal recurrence risk
- No specific long-term surveillance guidelines exist 4
Key Clinical Pitfalls
- Never assume complete resection without muscle in specimen - 49% of superficial disease is understaged when muscularis propria is absent 2
- Do not use BCG for immediate post-TURBT instillation - only chemotherapy should be used within 24 hours 2
- Avoid prolonged observation alone for high-grade disease - progression risk is substantial without adjuvant therapy
- Do not offer TURBT alone, radiotherapy alone, or chemotherapy alone as curative treatment for muscle-invasive disease 3